Thanks hottod, lots of useful info as always. I was intrigued by your note that Stoke only have one drug in clinical trials, with a prevalence of 1:15,700. They have 4 others in pre-clinical. It's market cap is A$1.13B.
PYC seems to have a stronger pipeline, but valued at A$780m. Just interesting to see the differences.
Three things possibly holding back PYC at the moment:
- Being in Australia - biotech backwater (from a financial perspective)
- Being low on cash - cap raise or deal..?
- Lack of exposure to build the buy-side
Hoping the next 6 months changes the last 2...?
Thanks again.
Thanks hottod, lots of useful info as always. I was intrigued by...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
0.020(1.59%) |
Mkt cap ! $743.6M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.28 | $1.24 | $46.67K | 37.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15857 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |